Specialty Chemicals Archives

PIDILITIND – Pidilite Industries – Q4 FY26 Earnings Call – 7-May-26

Pidilite’s topline resilience hinges on West Asia resolution and urban demand; margins face structural pressure from RM inflation unless pricing power holds; bottomline sensitivity to treasury and subsidiary volatility remains elevated.

1–2 minutes

Also see: PIDILITIND – Pidilite Industries – Q4 FY26 Financial Results – 7-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Conflict pauses but lingers, VAM stabilizes at $1,500/tonne, and demand moderates but remains positive. UVG grows 10–12% (FY27) with muted volume backlash from pricing. EBITDA margins compress to 20–22% due to lagged RM pass-through. Nina volatility persists, but Roff/Dr. Fixit offset with rural traction.

PIDILITIND – Pidilite Industries – Q4 FY26 Financial Results – 7-May-26

Pidilite’s FY26 strong: PAT +17.9%, 28.1% EBITDA margins, near‑zero debt, 90%+ FCF conversion. C&B compounding with leverage visible. Risks: DSO >54 days, dividend payout limiting reinvestment, CWIP doubling pressuring FCF if revenue lags. High‑quality compounder; valuation, not business quality, is the debate for FY27.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 11.1% YoY (₹13,140 Cr → ₹14,601 Cr), driven by volume-led expansion across both segments; C&B outpaced B2B at 11.4% vs 7.2%.
Q4FY26 revenue at ₹3,583 Cr grew 14.1% YoY over Q4FY25 (₹3,141 Cr), but declined 3.4% QoQ from Q3FY26 (₹3,710 Cr) — typical seasonal softness.
Inter-segment eliminations narrowed significantly (₹303 Cr → ₹245 Cr), indicating reduced internal trade, with external revenue quality improving.

Bottomline

PAT grew 17.9% YoY (₹2,096 Cr → ₹2,471 Cr), ahead of revenue growth — operating leverage is visible at scale.
Exceptional items dropped sharply to ₹13.7 Cr (FY26) from ₹24.9 Cr (FY25), meaning clean earnings quality improved further.
Effective tax rate held steady at ~25.4%, with minimal deferred tax drag — no tax-driven PAT distortion.

Margins

EBITDA margin expanded 131 bps to 28.1% — raw material intensity stable, while employee and other expense leverage improved.
PAT margin (consolidated) widened 98 bps to 16.93% — bottom-line efficiency compounding quietly.
B2B segment EBIT margin: ₹529 Cr on ₹3,211 Cr revenue = 16.5% vs C&B at ₹3,546 Cr on ₹11,574 Cr = 30.6%; structural margin gap between segments is wide and persists.

Growth Trajectory

Three-year PAT CAGR implied by FY25→FY26 base: 17.9% single-year step is strong; C&B segment profit grew 19% YoY, signaling consumer-facing pricing power is intact.
OCF grew 24.1% YoY (₹2,287 Cr → ₹2,837 Cr), faster than PAT — cash conversion ratio improved to 1.15x from 1.09x.
CWIP jumped from ₹129 Cr to ₹329 Cr — accelerating capex cycle signals capacity expansion ahead; sustaining margins through this investment phase is the key test.

ATUL – Atul Ltd – Q4 FY26 Financial Results – 24-Apr-26

Atul Ltd’s FY26 saw 40% PAT growth, margin gains, and tripled OCF on a debt‑free balance sheet. Life Science Chemicals EBIT at 23.1% and rising corpus signal durability. Risks: capex slowdown, MSME exposure, reliance on investment gains. FY27 hinges on capex revival.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 12.4% YoY (₹5,583 Cr → ₹6,274 Cr in FY26), with Q4FY26 accelerating to 15.1% YoY (₹1,452 Cr → ₹1,670 Cr) — momentum is building into year-end.
Performance & Other Chemicals dominates at 73.5% of FY26 segment revenue (₹4,609 Cr), growing 13.6% YoY; Life Science Chemicals contributed ₹1,805 Cr (+6.7% YoY) — both segments in sustained expansion.
Q4FY26 inter-segment revenue fell to ₹52 Cr from ₹64 Cr in Q4FY25, indicating less internal cross-charging and cleaner external revenue quality.

Bottomline

PAT attributable to owners surged 40.1% YoY (₹484 Cr → ₹678 Cr in FY26); Q4FY26 PAT jumped 66.2% YoY (₹127 Cr → ₹210 Cr) — the most decisive quarterly beat of the year.
Basic EPS expanded from ₹164.37 to ₹230.25 (+40.1% YoY), with no dilution — all earnings growth is owner-accruing.
A deferred tax charge of ₹39.6 Cr in FY26 (vs. ₹35.5 Cr in FY25) signals continued capex-linked timing differences; despite this, effective tax rate declined to 23.4% from 27.9%, partly aided by ₹14.2 Cr prior-year tax write-back in Q4.

Margins

EBITDA (PBT + Finance costs + D&A, ex-other income): FY26 = ₹900.5 − ₹202.9 + ₹17.4 + ₹322.1 = ₹1,037.1 Cr on revenue of ₹6,273.5 Cr → EBITDA margin of 16.5% vs. FY25: (₹692.5 − ₹109 + ₹24 + ₹316.8) = ₹924.3 Cr / ₹5,583.4 Cr = 16.6% — broadly stable.
Net profit margin (PAT attributable / Revenue): FY26 = ₹677.9 / ₹6,273.5 = 10.8% vs. FY25 = ₹483.9 / ₹5,583.4 = 8.7% — 210 bps expansion, a material quality improvement.
Power & fuel costs declined as a share of revenue (FY26: 10.3% vs. FY25: 11.7%), while material costs held at 51.9% — input efficiency is improving on the energy side.

Growth Trajectory

Revenue CAGR implied over FY25–FY26 is 12.4%; at Q4FY26 run-rate (₹1,670 Cr/quarter × 4 = ~₹6,680 Cr annualised), FY27 growth is tracking above trend.
Segment EBIT margin for Life Science Chemicals: FY26 = ₹417 Cr / ₹1,805 Cr = 23.1% vs. FY25 = ₹347 Cr / ₹1,692 Cr = 20.5% — 260 bps expansion; Performance Chemicals: 9.0% vs. 8.5% — incremental but consistent.
Other income nearly doubled YoY (₹109 Cr → ₹203 Cr), partly from investment gains (₹77 Cr FVTPL gains), suggesting the investment corpus is growing as a structural earnings contributor.

PIDILITIND – Q3 FY26 Earnings Call – 4-Feb-26

Pidilite’s revenue growth of 9–11% CAGR (base) driven by domestic resilience and adhesive penetration, with ±3% export variance. PAT CAGR at 12–15% (base) on 24–25% margins; bull case hinges on EU trade deal, bear case on shocks. EBITDA corridor: 20–24%.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) U.S. tariffs resolved by Q1 FY27 (exports flat YoY); (2) Tile adhesive penetration sustains 15–18% CAGR; (3) A&SP delivers +50 bps UVG uplift.
Outcome: Revenue growth 9–11%, EBITDA margin 24–25% (gross margin tailwinds offset by A&SP). Dr. Fixit/Roff outperform; pioneering segments contribute <5% revenue. Valuation supports 20–22x PE, in line with historical premium.